17-trifluoromethylphenyl trinor prostaglandin f2a

17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma, with unsubstituted or meta-substituted aromatic derivatives being the most potent FP receptor agonists. 17-trifluoromethylphenyl trinor PGF2α, which contains an aromatic ring reminiscent of the trifluoromethyl-phenoxy ring in travoprost ((+)-fluprostenol isopropyl ester), is expected to act similarly to the free acid form of travoprost as an ocular hypotensive agent. Additionally, 17-phenyl trinor PGF2α is a potent luteolytic and abortifacient with a potency equal to or greater than that of fluprostenol and cloprostenol.